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Skeletal homeostasis is dynamically infl  uenced 
by the immune system (1–3), and lymphocyte- 
or macrophage-derived cytokines are among 
the most potent mediators of osteoimmuno-
logical regulation (3–7). Therefore, the eff  ect 
of individual cytokines on bone cells has been 
extensively studied (3–7), but the subset of im-
mune cells with selective cytokine production 
that specifi  cally aff  ects bone cell diff  erentiation 
has not been well characterized. Upon acti-
vation, CD4+ T cells undergo distinct devel-
opmental pathways to the specialized eff  ector 
subsets: Th1 cells produce IFN-γ and regulate 
cellular immunity, whereas Th2 cells produce 
IL-4 and IL-5 and mediate humoral immunity 
(8). In addition, accumulating evidence sug-
gests that newly recognized IL-17–producing T 
(Th17) cells have a crucial role in autoimmune 
infl   ammation (9, 10). CD4+CD25+Foxp3+ 
regulatory T (T reg) cells also constitute a dis-
tinct subset that prevents immune pathology 
through suppression of pathogenic T cells (11). 
Activation of CD4+ T cells is often linked to 
pathological bone resorption (3, 4), but the dis-
tinct CD4+ T cell subset that induces the dif-
ferentiation of bone-resorbing osteoclasts has 
not been identifi  ed (2, 3).
Osteoclasts are multinucleated cells (MNCs) 
of monocyte/macrophage lineage that degrade 
bone matrix and dynamically remodel the 
skeleton (4–6). The generation of osteoclasts 
is physiologically supported by mesenchymal 
cells such as osteoblasts, which provide essen-
tial signals for diff  erentiation of the osteoclast 
lineage: macrophage colony-stimulating   factor 
(M-CSF), receptor activator of NF-κB ligand 
(RANKL), and costimulatory signals for RANKL 
(12). RANKL is the key osteoclastogenic cyto-
kine expressed by osteoclastogenesis-  supporting 
mesenchymal cells, but the same molecule has 
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In autoimmune arthritis, traditionally classifi  ed as a T helper (Th) type 1 disease, the acti-
vation of T cells results in bone destruction mediated by osteoclasts, but how T cells en-
hance osteoclastogenesis despite the anti-osteoclastogenic effect of interferon (IFN)-𝗄 
remains to be elucidated. Here, we examine the effect of various Th cell subsets on osteo-
clastogenesis and identify Th17, a specialized infl  ammatory subset, as an osteoclastogenic 
Th cell subset that links T cell activation and bone resorption. The interleukin (IL)-23–IL-17 
axis, rather than the IL-12–IFN-𝗄 axis, is critical not only for the onset phase, but also for 
the bone destruction phase of autoimmune arthritis. Thus, Th17 is a powerful therapeutic 
target for the bone destruction associated with T cell activation.
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been shown to be expressed by T cells, indicating that 
RANKL is a molecule that bridges the skeletal and immune 
systems (4).
In autoimmune arthritis, bone destruction is attributable to 
excessive bone resorption by osteoclasts, the formation of 
which is directly and indirectly regulated by CD4+ T cells 
infi   ltrating into the lesion (2, 3, 13, 14). Indirect eff  ects 
are mainly mediated by infl  ammatory cytokines produced by 
  macrophage-like synovial cells such as TNF-α and IL-1 that 
induce RANKL on synovial fi  broblasts (14–16), but it is poorly 
understood how T cells exert direct eff  ects (3). Although T 
cells express RANKL, the T cell–mediated positive eff  ect is 
not easily observed because T cells also produce IFN-γ, which 
counterbalances the eff  ect of the RANKL, making the net ef-
fect on osteoclastogenesis inhibitory (3, 13, 14). Although au-
toimmune arthritis has traditionally been assumed to be a Th1 
disease (17, 18), there is controversy over the role of Th1 cells 
in the onset phase of the disease based on the observations that 
typical Th1 cytokines, such as IFN-γ, are not always highly 
expressed in the lesion (19, 20), and that collagen-induced ar-
thritis is exacerbated in mice lacking IFN-γ signaling (21, 22). 
Therefore, neither bone destruction nor infl  ammation may be 
attributable to Th1 cells. It is a critically important issue to de-
termine the type of T cells linked to the activated osteoclasto-
genesis under such infl  ammatory conditions.
Recently, it has been reported that the IL-23–IL-17 axis, 
rather than the IL-12–IFN-γ axis, is critical for the onset of 
autoimmune arthritis (23, 24). It is also reported that IL-17 is 
detectable in the synovial fl  uid from rheumatoid arthritis (RA) 
patients and enhances osteoclastogenesis by inducing RANKL 
on mesenchymal cells (25). Here, we explored the eff  ects of 
various CD4+ T cell subsets on osteoclast diff  erentiation and 
identifi  ed Th17 cells as the exclusive osteoclastogenic T cell 
subset among the known CD4+ T cell lineages. The impor-
tance of the IL-23–IL-17 axis in the bone destruction phase 
was underscored by the observations in mice lacking either 
IL-17 or IL-23 (p19). We also found that the mRNA expres-
sion of RANKL correlates with that of IL-23 (IL23A), but 
not that of IL-12 (IL12A), in the synovial tissues of RA pa-
tients. Collectively, these results suggest that autoimmune ar-
thritis can be deemed a Th17-type disease in terms of both the 
onset and destruction phases and provide a molecular basis for 
targeting the IL-23–IL-17 axis in the treatment of RA.
RESULTS
Effects of Th1, Th2, and T reg cells on osteoclastogenesis
Although the eff  ects of activated T cells on osteoclastogenesis 
have been documented in previous reports (13, 14, 26), these 
Figure 1.  Effects of Th1, Th2, and T reg cells on in vitro osteo-
clastogenesis. (A) Schematics of two culture systems for osteoclast dif-
ferentiation and Th cell addition. In the RANKL–M-CSF system, mouse 
nonadherent BMCs were stimulated with M-CSF for 2 d and adherent 
cells were used as BMMs. After BMMs were stimulated with recombinant 
RANKL and M-CSF for 3 d, the formation of TRAP+ MNCs was analyzed. 
In the co-culture system, BMCs were co-cultured with osteoblasts stimu-
lated with VitD3 and PGE2, and the formation of TRAP+ MNCs was ob-
served 7 d after the addition of BMCs. (B) Inhibitory effects of Th1 and 
Th2 cells on TRAP+ MNC formation in the RANKL–M-CSF system. Th cells 
(4,000 or 20,000 cells/ml) were added at the same time as RANKL (day 0) 
with (black bars) or without (white bars) anti-CD3 mAb. n.d., not detected. 
(C) Inhibitory effects of Th1 and Th2 cells on TRAP+ MNC formation in the 
co-culture system. The same number of T cells as in B was added 2 d after 
BMC addition (day 2). (D) Microphotographs of the in vitro osteoclast 
formation systems in the presence of Th1 or Th2 cells (20,000 cells/ml) 
with anti-CD3 mAb (TRAP staining). (E) Cytokine profi  le of culture super-
natants in the presence of Th cells and 1 μg/ml of soluble anti-CD3 mAb 
(the RANKL–M-CSF system on day 2). Without restimulation by anti-CD3 
mAb, cytokine production was much less than this result and was diffi  cult 
to detect after 2-d culture with osteoclast precursor cells (not depicted). 
(F) Effects of Th1 and Th2 cells (20,000 cells/ml plus anti-CD3 mAb) on 
WT or IFN-γ receptor–defi  cient (Ifngr1−/−) osteoclast precursor cells. 
(G) Effects of isolated CD4+CD25+ T reg cells (4,000 or 20,000 cells/ml plus 
anti-CD3 mAb) on osteoclastogenesis in vitro. n.s., not signifi  cantly different. 
The survival of a considerable number of T reg cells after 3 d was 
 confi  rmed by CFSE staining (not depicted).JEM VOL. 203, November 27, 2006  2675
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T cells were only stimulated by anti-CD3 antibody or PMA 
and the characterization of the T cells was not strictly per-
formed. In this study, to investigate the eff  ects of eff  ector Th 
cell subsets on osteoclastogenesis, we added Th subsets, which 
were strictly developed under Th1 or Th2 conditions. Puri-
fi  ed CD4+ T cells were stimulated with anti-CD3/CD28 
mAbs in the presence of either IL-12 (with anti–IL-4 mAb) 
or IL-4 (with anti–IFN-γ mAb) for Th1 or Th2 polarization. 
The Th cells were added to the two types of in vitro osteo-
clast diff  erentiation systems: osteoclast precursor cells derived 
from BM cells (BMCs) were stimulated with recombinant 
RANKL and M-CSF (the RANKL–M-CSF system), or co-
cultured with osteoblasts in the presence of 1,25 (OH)2 vita-
min D3 (VitD3) and prostaglandin E2 (PGE2) (the co-culture 
system), and the formation of MNCs stained for tartrate-
  resistant acid phosphatase (TRAP), a marker enzyme for osteo-
clasts, was evaluated (Fig. 1 A). When Th1 or Th2 cells were 
added to the RANKL–M-CSF system at the same time as 
RANKL, both subsets had a marked inhibitory eff  ect on the 
formation of TRAP+ MNCs and the inhibitory eff  ects were 
dependent on the number of added T cells (Fig. 1, B and D). 
These inhibitory eff  ects were signifi  cantly enhanced by re-
stimulation with soluble anti-CD3 mAb, suggesting that re-
stimulation of T cell receptor augments the polarized cytokine 
secretion and the inhibitory eff  ects on osteoclastogenesis. If 
Th1 or Th2 cells were added to the co-culture system 2 d 
  after BMC addition, the inhibitory eff  ects of both subsets on 
osteoclastogenesis were exerted only by T cells restimulated 
with anti-CD3 mAb (Fig. 1, C and D). Th1 and Th2 cells 
both had less suppressive eff  ects in the co-culture system, 
possibly because osteoblasts provide protection against the 
  inhibitory eff  ects through costimulatory signals (27) (see 
  Discussion). As expected, the Th1 and Th2 subsets used in 
these experiments produced a signifi  cant amount of IFN-γ and 
IL-4, respectively (Fig. 1 E). The inhibitory eff  ects of Th1 
cells on osteoclastogenesis were completely abrogated on the 
BM-derived monocyte/macrophage precursor cells (BMMs) 
derived from IFN-γ receptor–defi  cient (Ifngr1−/−) mice (28), 
indicating that IFN-γ is responsible for the Th1 cell– mediated 
inhibition of osteoclastogenesis (Fig. 1 F). We further  analyzed 
the eff  ects of CD4+CD25+ T reg cells on osteoclastogenesis 
in both systems, but they were found to have neither an 
enhancing nor an inhibitory eff  ect (Fig. 1 G), suggesting that 
T reg cells are not directly related to the T cell–mediated 
regulation of bone resorption.
Characterization of MNCs induced by Th2 cells and IL-4
It has been reported that the inhibitory eff  ect of IFN-γ on 
osteoclastogenesis is reduced if the osteoclast precursor cells 
encounter RANKL before IFN-γ stimulation, suggesting 
that RANKL-prestimulated preosteoclasts are resistant to 
such inhibitory cytokines (29). To test whether the inhibi-
tory eff  ects of Th cells on osteoclastogenesis are also depen-
dent on the diff  erentiation stage of the osteoclast precursor 
cells, we added the Th cells to the osteoclast formation sys-
tems 1 d later than in the previous experiment. Interestingly, 
the inhibitory eff  ects of Th cells were less (Fig. 2 A). Al-
though Th1 cells inhibited the formation of TRAP+ MNCs 
under this condition, Th2 cells induced a normal number of 
TRAP+ MNCs in the RANKL–M-CSF system and even an 
increased number in the co-culture system (Fig. 2 A).
Figure 2.  Formation of multinuclear cells with no bone-resorbing 
activity induced by Th2 cells and IL-4. (A) Inhibitory effects of Th1 and 
Th2 cells on osteoclastogenesis are reduced when T cells are added 1 d 
later. Th cells (20,000 cells/ml plus anti-CD3 mAb) were added on days 0 
(at the same time as RANKL, gray bars) or 1 (black bars) to the RANKL–M-CSF 
system and on days 2 (2 d after BMC addition, gray bars) or 3 (black bars) 
to the co-culture system. (B) Microphotographs and (C) quantifi  cation of in 
vitro osteoclast formation (left, TRAP staining) and resorption pit forma-
tion (right). Th1 and Th2 cells (20,000 cells/ml plus anti-CD3 mAb) were 
added to WT or Stat6−/− osteoclast precursor cells on day 1. (D) Effect of 
IL-4 on mRNA expression of osteoclast-related genes in osteoclast precur-
sor cells (GeneChip analysis). Osteoclast precursor cells were stimulated by 
10 ng/ml IL-4 from day 1 in the RANKL–M-CSF system and harvested on 
day 3. Fold mRNA difference was calculated by dividing the average differ-
ence of the IL-4–treated sample by that of the control sample. The expres-
sions of most of the osteoclast-specific genes are down-regulated. 
(E) Reduced expression of NFATc1 protein in the cells treated with IL-4. 
Osteoclast precursor cells were stimulated by 10 ng/ml IL-4 from day 1 in 
the RANKL–M-CSF system, fi  xed on day 3, and stained with anti-NFATc1 
antibody followed by Alexa Fluoro 488–labeled secondary antibody. 2676  TH17 AS AN OSTEOCLASTOGENIC TH CELL SUBSET | Sato et al.
These results appeared to suggest that Th2 cells increase 
osteoclastogenesis under certain conditions, but the MNCs 
induced in the presence of Th2 cells were only weakly stained 
for TRAP (TRAPdim) and were incapable of bone resorption 
(Fig. 2, B and C). Even in the presence of Th2 cells, TRAP+ 
MNCs with bone-resorbing activity were formed from 
BMMs derived from mice defi  cient in Stat6, which is an es-
sential mediator of IL-4 signaling (30), suggesting that IL-4 is 
involved in the formation of TRAPdim MNCs. Consistent 
with this, the addition of IL-4 to the RANKL–M-CSF sys-
tem at the same time as RANKL strongly inhibited TRAP+ 
MNC formation, and the addition of IL-4 1 d later induced 
TRAPdim MNCs (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20061775/DC1). The eff  ects of IL-4 
were abrogated if added to Stat6-defi  cient cells, which gen-
erated TRAP+ MNCs that were able to resorb bone.
To further characterize the TRAPdim MNCs induced by 
Th2 cells through IL-4, we performed a genome-wide mi-
croarray screening of the genes expressed in the TRAPdim 
MNCs (31). TRAPdim MNCs induced by IL-4 expressed 
a high level of genes characteristic of activated macrophages, 
including chemokine ligands and enzymes involved in aller-
gic responses (Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20061775/DC1). The expression of most 
of the genes important for osteoclast diff  erentiation or func-
tions was decreased (Fig. 2 D). The expression of NFATc1, 
an essential transcription factor for osteoclastogenesis (31, 32), 
was also revealed to be down-regulated by immunostaining 
(Fig. 2 E). Thus, the TRAPdim MNCs induced by Th2 cells 
are not authentic osteoclasts but rather should be classifi  ed as 
macrophage polykarions.
Th17 cells stimulate osteoclastogenesis through 
osteoclastogenesis-supporting cells
Because the above results show that neither Th1, Th2, nor T 
reg cells enhance osteoclastogenesis, we next focused on a 
newly identifi  ed CD4+ T cell subset producing IL-17 called 
Th17 (33, 34). We suspected the Th17 subset to be a good 
candidate for the osteoclastogenic Th subset because it has 
been reported that IL-17 induces RANKL on mesenchymal 
cells and promotes osteoclastogenesis in vitro (25). More-
over, Th17 cells, which produce IL-17 (IL-17A) and its re-
lated cytokines such as IL-17F, but not IFN-γ or IL-4, are 
responsible for a variety of autoimmune infl  ammatory eff  ects 
(9, 10). Recent studies suggest that TGF-β and IL-6 are es-
sential for the initiation of Th17 diff  erentiation and IL-23 is 
critical for expanding the population (35, 36). IL-23 is one of 
the IL-12 family cytokines and is a heterodimer consisting of 
the subunits p40 and p19 (9, 10). Even though IL-23 shares 
a p40 subunit and one of its receptor subunits (IL-12β1) with 
Figure 3.  Enhanced osteoclastogenesis by Th17 cells in the co-
culture system but not in the RANKL–M-CSF system. (A) Effects of 
Th1 and Th17 cells on the osteoclast differentiation systems. T cells (4,000 
or 20,000 cells/ml plus anti-CD3 mAb) were added on day 1 to the 
RANKL–M-CSF system and on day 3 to the co-culture system. When the 
Th17 cells were added 1 d earlier, or in the absence of soluble anti-CD3 
mAb, enhancement of osteoclastogenesis was not observed even in the 
co-culture system (not depicted). (B) Cytokine profi  le of the culture super-
natants obtained on day 3 from the RANKL–M-CSF system in the pres-
ence of Th1 and Th17 cells derived from either WT or Il17−/− mice under 
the conditions described in A. (C) Effects of Th1 and Th17 cells derived 
from either WT or Il17−/− mice on the formation of TRAP+ MNCs or 
TRAP+ cells in the co-culture system in the absence of VitD3 and PGE2. 
T cells (20,000 cells/ml plus anti-CD3 mAb) were added on day 3. (D) Effects 
of recombinant IL-17 and IL-23 (2 or 10 ng/ml) on osteoclastogenesis in 
vitro. (E) Expression of RANKL on Th subsets. CD4+ T cells cultured in each 
of the Th conditions for 3 d were restimulated with 1 μg/ml of plate-
bound anti-CD3 mAb for 4 h and subjected to fl  ow cytometric analysis 
using anti-RANKL mAb. Without the restimulation by anti-CD3 mAb, 
RANKL expression was barely detectable (not depicted).JEM VOL. 203, November 27, 2006  2677
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IL-12, IL-23 and IL-12 selectively play critical roles in the 
regulation of Th1 and Th17 polarization, respectively.
To obtain the Th17 cells, we stimulated CD4+ T cells 
with anti-CD3/CD28 mAbs in the presence of IL-23, anti–
IFN-γ mAb, and anti–IL-4 mAb. In the presence of Th17 
cells, TRAP+ MNCs were effi   ciently formed in the RANKL–
M-CSF system (Fig. 3 A) and possessed bone-resorbing ac-
tivity (not depicted), although the effi   ciency is a little less 
than in the control culture without the T cells. Moreover, in 
the co-culture system, the Th17 cells signifi  cantly enhanced 
the formation of TRAP+ MNCs (Fig. 3 A). Consistent with the 
previous reports, Th17 cells used in the above experiments 
produced a large amount of IL-17 but little IFN-γ, but Th1 
cells did the opposite (Fig. 3 B). When Th17 cells were added 
to the co-culture system even in the absence of VitD3 and 
PGE2, the formation of TRAP+ MNCs was observed (Fig. 
3 C). The osteoclastogenic eff  ects of Th17 cells in the co-
culture system was greatly reduced when we used Th17 cells 
derived from Il17−/− mice (37), indicating that the IL-17 
produced from Th17 cells is mainly responsible for the osteo-
clastogenic eff  ects of Th17 cells. IL-23 or IL-17 had no eff  ect 
on osteoclastogenesis in the RANKL–M-CSF system, but 
IL-17 promoted osteoclastogenesis in the co-culture system, 
suggesting that IL-17 does not directly act on osteoclast pre-
cursor cells but rather on osteoclastogenesis-supporting cells 
(Fig. 3 D). This is consistent with the previous report that 
IL-17 promotes osteoclastogenesis through the induction of 
RANKL on osteoblastic cells (25). These results show that 
Th17 is the only osteoclastogenic Th subset according to 
the currently accepted categorization of CD4+ T cells, and 
that Th17 cells facilitate osteoclastogenesis, possibly through 
IL-17–mediated induction of RANKL on osteoblastic cells.
We evaluated the expression level of RANKL on the sur-
face of Th cells and found that Th17 cells express a signifi  cant 
amount of RANKL, but Th1 cells express only a minimal 
amount (Fig. 3 E). Neither subset, however, exhibited pro-
motive eff  ects on osteoclastogenesis in the RANKL–M-CSF 
system (Fig. 3 A) or induced any TRAP+ cells when added 
to the BMM culture in the absence of exogenous soluble 
RANKL (not depicted). Thus, it is evident that the RANKL 
expressed by Th cells alone is not suffi   cient to activate osteo-
clastogenesis (see Discussion).
The IL-23–IL-17 axis plays a critical 
role in infl  ammation-induced bone destruction in vivo
To clarify the role IL-17 and IL-23 play in bone metabolism 
in vivo, we investigated the phenotype of Il17−/− and 
Il23a−/− (lacking p19) (38) mice. There was no signifi  cant 
diff  erence in bone mineral density as evaluated by dual- 
  energy x-ray absorptiometry (Fig. 4 A). Microradiography also 
Figure 4.  Contribution of IL-17 and IL-23 to the physiological and 
pathological bone resorption. (A) Bone mineral densities (measured in 
20 longitudinal divisions of the femurs), (B) micro-computed tomography 
(at 10% length above the distal epiphyseal plate), and (C) bone morphometic 
analyses of WT, Il17−/−, and Il23a−/− mice at the age of 12 wk. (D) Histological 
examination of calvarial bones of WT, Il17−/−, and Il23a−/− mice treated with 
LPS (hematoxylin and TRAP staining). The degree of bone destruction was 
analyzed by the number of osteoclasts and the area of the eroded surface (%).2678  TH17 AS AN OSTEOCLASTOGENIC TH CELL SUBSET | Sato et al.
revealed no obvious abnormality in skeletal development 
(Fig. 4 B). Bone morphometric analyses revealed the param-
eters of bone resorption and formation to be normal even in 
the mutant mice (Fig. 4 C), indicating that neither IL-17 nor 
IL-23 is involved in the physiological regulation of bone 
homeostasis.
To further investigate the role of IL-17 and IL-23 in the 
disease conditions characterized by enhanced osteoclastogen-
esis associated with T cell activation, we used an LPS-
induced model of infl  ammatory bone destruction, which is not 
induced by an autoantigen but is T cell dependent (14, 39). 
Because it is well documented that IL-17 and IL-23 play an 
important role in the development of autoimmune arthritis 
(23, 24), we used this infl  ammatory bone destruction model 
to evaluate their role in the osteoclast-mediated destruction 
phase. LPS injection into the calvarial bone results in severe 
bone destruction associated with aberrant formation of osteo-
clasts in WT mice, but the level of bone destruction was 
much less pronounced and the osteoclast formation was sig-
nifi  cantly reduced in both the Il17−/− mice and Il23a−/− 
mice (Fig. 4 D). These results suggest that the Th17 cells 
  expanded through IL-23 stimulation are involved in the 
T cell–mediated osteoclastogenesis in vivo. In contrast, the 
bone destruction was enhanced and a greater number of os-
teoclasts were formed in Ifngr1−/− Stat6−/− mice, which are 
defi  cient in the response to both IFN-γ and IL-4 (Fig. 4 D), 
suggesting that IFN-γ and IL-4 may play a protective role 
against bone destruction by suppressing osteoclastogenesis as-
sociated with infl  ammation.
The above results suggest that IL-23–stimulated prolifera-
tion of Th17 cells, a major osteoclastogenic Th subset, plays 
a pivotal role in infl  ammatory bone destruction by inducing 
RANKL through an IL-17 eff   ect on mesenchymal cells. 
Consistent with this, it has been reported that RANKL is 
abundantly expressed in the synovial fi  broblasts of RA pa-
tients (16, 40) and the IL-17 concentration is elevated in the 
synovial fl  uid of RA patients (25). To explore the role of 
IL-23 in the induction of RANKL in RA, we investigated 
whether IL-23 was detected in the synovium of RA patients. 
Quantitative RT-PCR analysis revealed the mRNA of the 
p19 subunit of IL-23 (IL23A) in all the samples of the 
synovium derived from RA patients, and the expression level 
of IL23A positively correlated with that of RANKL (Fig. 5 A). 
A similar correlation was observed between RANKL and 
the p40 subunit shared by IL-12 and IL-23 (IL12B), but the 
expression of the p35 subunit specifi  c for IL-12 (IL12A) did 
not correlate with that of RANKL, suggesting that IL-23 is 
an important determinant of arthritic bone destruction 
through the induction of RANKL. These results lend further 
support to the notion that the IL-23–IL-17 axis, rather than 
the IL-12–IFN-γ axis, is critical for the bone destruction 
phase of autoimmune arthritis.
DISCUSSION
Coordinated activation of the innate and adaptive immune 
systems is essential for the effi   cient eradication of pathogens, 
but aberrant or prolonged activation under certain pathologi-
cal conditions, such as autoimmune infl  ammation, results in 
tissue damage through the activation of eff  ector cells. In au-
toimmune arthritis, it has long been a challenging question as 
to how the abnormality of the immune system induces the 
skeletal damage, although the infi  ltration of CD4+ T cells in 
the RA synovium is a pathogenetic hallmark and is undoubt-
edly linked to the bone destruction that ensues (3, 13, 14, 
20). After RANKL was cloned and the high RANKL ex-
pression in the synovium was brought to light (16, 40), the 
importance of bone-resorbing osteoclasts came into general 
acceptance (3). Based on recent reports using genetically 
modifi  ed mice, the crucial role of osteoclasts in the infl  am-
matory bone loss has been established (41, 42), but which 
CD4+ T cells cause the induction of osteoclasts, and by what 
mechanism, has remained elusive.
As RANKL is expressed in activated T cells, T cells may 
have the capacity to induce osteoclast diff  erentiation by di-
rectly acting on osteoclast precursor cells (13, 26). However, 
because T cells also secrete a variety of cytokines and express 
membrane-bound factors other than RANKL, the eff  ects of 
T cells on osteoclastogenesis should be dependent on the bal-
ance of positive and negative factors expressed by the T cells. 
As summarized in Fig. 5 B, the results in this study show that 
Th1 and Th2 cells inhibit osteoclastogenesis by acting on the 
precursor cells, mainly through IFN-γ and IL-4, respectively. 
Figure 5.  Regulation of RANKL-mediated osteoclastogenesis by 
the IL-23–IL-17 axis in the RA synovial tissue. (A) Correlation of the 
mRNA expression level of RANKL with that of IL23A (p19), IL12A (p35), or 
IL12B (p40) in the synovium of RA patients. The relative expressions of 
RANKL, IL23A, IL12A, and IL12B were all standardized using that of 
GAPDH. (B) Model of Th17-mediated bone destruction in autoimmune 
arthritis. Th17 cells function as an osteoclastogenic Th cell subset by stim-
ulating local inflammation, inducing RANKL on osteoclastogenesis-
  supporting cells, and expressing RANKL on themselves, all of which 
contribute to an acceleration of osteoclastogenesis. It is notable that 
RANKL on Th17 cells alone is not suffi  cient for the induction of osteoclast 
differentiation (a dotted line). See Discussion for the details. Op, osteo-
clast precursor cell.JEM VOL. 203, November 27, 2006  2679
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The inhibitory eff  ects of these cytokines were less observed 
in the co-culture system than in the RANKL–M-CSF system 
(Figs. 1, B and C, and 2 A). We infer that osteoblasts may 
provide membrane-bound RANKL and stimulate costimula-
tory signals for RANKL simultaneously, enabling the strong 
cell–cell contact between osteoblasts and osteoclast precursor 
cells and preventing the access of T cells or inhibitory cyto-
kines to osteoclast precursor cells.
Previous observations that IL-12 and IL-18, which drive 
Th1 diff  erentiation, both inhibit osteoclastogenesis via IFN-γ 
or GM-CSF (43, 44), and that IL-10, which is released 
from Th2 cells, also negatively regulates osteoclastogenesis 
(45) further support the negative role of Th1 and Th2 cells 
on osteoclastogenesis. In contrast, Th17 cells stimulated by 
IL-23 promote osteoclastogenesis mostly through production 
of IL-17 (Fig. 3, A and C). Therefore, the osteoclastogenic 
ability of Th17 cells does not require cell–cell contact with 
osteoclast precursor cells, but additional membrane-bound 
mediators such as RANKL and CD40L may also contribute 
(46, 47). IL-17 is known to act on the osteoclastogenesis-
supporting cells to induce RANKL (25). It should be noted 
that the eff  ect of IL-17 is not limited to this direct eff  ect on 
the osteoclastogenesis-supporting cells. IL-17 facilitates local 
infl   ammation by recruiting and activating immune cells, 
which leads to an abundance of infl  ammatory cytokines such 
as TNF-α and IL-1 (9, 10). The infl  ammatory cytokines en-
hance RANKL expression on osteoclastogenesis-supporting 
cells and activate osteoclast precursor cells by synergizing 
with RANKL signaling. A relatively high expression of 
RANKL on Th17 cells may also participate in the enhanced 
osteoclastogenesis (Fig. 3 E). Collectively, Th17 cells can be 
called an osteoclastogenic Th subset not only because Th17 
cells have positive eff  ects on osteoclastogenesis in vitro, but 
also because they tip the balance of the microenvironments in 
favor of osteoclast diff  erentiation.
It is worth noting that Th17 cells do not induce osteo-
clastogenesis in the absence of osteoblasts. This strongly sug-
gests that RANKL expressed on Th17 cells alone is not 
suffi   cient to induce osteoclastogenesis, although this is partly 
because even Th17 cells produce a small amount of IFN-γ, 
which counterbalances the RANKL action. To understand 
the role of RANKL on T cells in more detail, we need mice 
of T cell–specifi  c ablation of the RANKL gene, which are 
currently unavailable. But it is conceivable that RANKL ex-
pressed on adherent cells such as osteoblasts has more potent 
eff  ects than that expressed on T cells. This mechanism may 
also explain why osteoclasts are formed only in the bone 
  microenvironments, but it currently remains to be clarifi  ed. 
We consider the following explanations: (a) T cell expres-
sion of membrane-bound RANKL, which is more osteo-
clastogenic than the soluble form (48), is very low compared 
with that on osteoblasts; (b) costimulatory signals provided 
specifi  cally by osteoblasts (12, 27) are missing in T cells; and 
(c) cell adhesion induces specifi   c signals including those 
  mediated by integrins, which are also important for osteo-
clastogenesis (49).
In our study, T reg cells had no apparent eff  ect on osteo-
clastogenesis in vitro (Fig. 1 G). However, their function 
in the regulation of bone metabolism should be investigated 
in vivo considering the recent fi  nding that the development 
of Th17 cells and T reg cells is coordinately regulated 
(10, 35, 36).
The importance of the IL-23–IL-17 axis in the autoim-
mune infl  ammation has been demonstrated in a variety of 
models of autoimmune diseases such as arthritis and encepha-
lomyelitis (23, 24, 38). In arthritis models, IL-17−/− mice 
were protected from the development of destructive arthritis 
(24), whereas collagen-induced arthritis is exacerbated in 
IFN-γ receptor–defi  cient mice (21, 22). The specifi  c role of 
IL-23 compared with IL-12 in the development of arthritis 
has been clearly demonstrated by a genetic study using mice 
defi  cient in p19 and p35 (23). Based on these observations, 
the IL-23–IL-17 axis inducing Th17 cells, rather than the 
IL-12–IFN-γ axis inducing Th1 cells, is critical for the develop-
ment of autoimmune arthritis. Our study also provides evi-
dence that the IL-23–IL-17 axis plays a critical role even in a 
model of bone loss induced by local infl  ammation that is 
independent of autoimmunity (Fig. 4 D), suggesting that 
the IL-23–IL-17 axis is not only essential for the onset phase, 
but also for the destruction phase of autoimmune arthritis 
characterized by the T cell–mediated activation of osteoclas-
togenesis. Thus, Th17 cells, an osteoclastogenic subset, have 
profound relevance in the bone damage that takes place in 
autoimmune arthritis. The identifi  cation of T cell subsets in 
the synovium of arthritis is a challenging issue of great impor-
tance that should be pursued in a future study. Considering 
the strong inhibitory eff  ects of Th1 cells on osteoclastogene-
sis, Th17 cells may be overwhelmingly dominant and the co-
localization of Th1 cells is unlikely, at least under the 
microenvironments in which osteoclastogenesis effi   ciently 
occurs. The positive correlation between IL-23 and RANKL 
expression in the synovium of RA patients further suggests 
the importance of IL-23 in the regulation of local osteoclas-
togenesis through IL-17 (Fig. 5 A). Despite the importance 
of TGF-β and IL-6 in the initiation of Th17 development 
(10, 35, 36), Th17 cells can be obtained in an IL-23–stimulated 
culture system without adding exogenous TGF-β/IL-6, 
suggesting that the endogenous level of TGF-β/IL-6 may 
suffi   ce for the initiation and that osteoclastogenic activity of 
Th17 cells is mainly determined by IL-23 under certain path-
ological conditions.
For the treatment of RA, there are several drugs available, 
most of which were developed to modulate immune reac-
tions. The antirheumatic drugs are eff  ective in treating pain 
and infl  ammation, but patients still fairly frequently have to 
undergo joint replacement surgery because of the progressive 
bone damage despite long-term treatment with antirheu-
matic drugs. Therefore, it is clinically an urgent issue to estab-
lish a method to prevent such persistent bone destruction (3). 
Although rheumatologists are now aware of the great impact 
that anti-TNF therapy has had on the management of RA 
(50), it is still not determined whether all patients respond 2680  TH17 AS AN OSTEOCLASTOGENIC TH CELL SUBSET | Sato et al.
to the therapy or, indeed, whether bone destruction will be 
completely prevented by it. Recent progress in   understanding 
the mechanism of bone loss in RA has provided promising 
new strategies, one of which is an anti-RANKL antibody 
directly suppressing RANKL-mediated osteoclastogenesis 
(51). As we have demonstrated a new role of Th17 in the 
context of bone damage in RA, the signifi  cance of the IL-23–
IL-17 axis extends beyond the simple initiation or develop-
ment of the autoimmunity. Because osteoclastogenic Th17 
cells link the autoimmune infl  ammation to bone damage, 
  inhibition of this axis has the potential of a doubly benefi  cial 
impact on RA, i.e., in the context of both the immune and 
skeletal systems, and thus appears to be an ideal therapeutic 
strategy for ameliorating the bone destruction associated with 
T cell activation.
MATERIALS AND METHODS
Mice. Ifngr1−/− (28), Stat6−/− (30), Il17−/− (37), and Il23a−/− mice (38) 
were described previously. All the mice were maintained under specifi  c 
pathogen-free conditions and were backcrossed to C57BL/6 mice. All ani-
mal experiments were performed with the approval of the Animal Study 
Committee of Tokyo Medical and Dental University and conformed to rel-
evant guidelines and laws.
Analysis of bone phenotype and LPS-induced bone destruction. 
The mice were subjected to histomorphometric and microradiographic ex-
aminations as described previously (27). 8-wk-old mice were injected with 
25 mg/kg body weight LPS (Sigma-Aldrich) subperiosteally in the calvarial 
bone. After 5 d, calvarial bones were analyzed as described previously using 
decalcifi  ed paraffi   n sections (14).
In vitro assays for osteoclast diff  erentiation and function. In vitro 
  osteoclast diff  erentiation was described previously (27, 52). For the RANKL–
M-CSF system, we cultured BMCs with 10 ng/ml M-CSF (R&D Systems) 
for 2 d and used them as BMMs. The cells were cultured with 50 ng/ml 
RANKL (PeproTech) and 10 ng/ml M-CSF for 3 d, and TRAP+ multi-
nucleated (more than three nuclei) cells were counted. The co-culture of os-
teoblasts derived from mouse calvarial cells and BMCs was performed in the 
presence of 10−8 M VitD3 (Wako) and 10−6 M PGE2 (Wako) for 7 d. For 
the assessment of the bone-resorbing function of osteoclasts, we cultured os-
teoclast precursors on a hydroxy appatite–coated disc (Osteologic; BD Bio-
sciences). After the culture period, the cells were washed away as described 
in the manufacturer’s protocol by 6% NaOCl and 5.2% NaCl.
Th cell diff  erentiation. CD4+ T cells were purifi  ed from the spleen using 
a magnetic sorter and anti-CD4 microbeads (MACS; Miltenyi Biotec). The 
purity of the CD4+ T cells was >95%. These CD4+ T cells were stimulated 
with a plate-bound anti-CD3 mAb and anti-CD28 mAb (1 μg/ml each) for 
3 d in the presence of (a) 10 ng/ml IL-12 and 10 μg/ml anti–IL-4 mAb for 
the Th1 cells, (b) 10 ng/ml IL-4 and 10 μg/ml anti–IFN-γ mAb for the Th2 
cells, and (c) 10 ng/ml IL-23 along with 10 μg/ml each of anti–IFN-γ and 
anti–IL-4 mAbs for the Th17 cells. When indicated, the T cells were added 
to the culture system with 1 μg/ml anti-CD3 mAb for restimulation. All the 
antibodies were purchased from BD Biosciences except for the anti-RANKL 
mAb (provided by H. Yagita, Juntendo University School of Medicine, 
  Tokyo, Japan). Recombinant IL-17 and the other cytokines were purchased 
from Genzyme and R&D Systems, respectively. T reg cells were purifi  ed 
using a MACS CD4+CD25+ Regulatory T Cell Isolation kit.
Analysis of mRNAs expressed in RA synovial tissues. Synovial tissues 
were obtained at the time of total knee arthroplasty from fi  ve patients (age 
range, 55–70 yr) who fulfi  lled the American College of Rheumatology cri-
teria and gave informed consent (16). The experiments were performed with 
the approval of the institutional ethical committee. The tissues were minced 
and homogenized in Sepasol-RNA (Nacalai Tesque), and total RNA was 
extracted and purifi  ed according to the manufacturer’s protocol.
GeneChip analysis and quantitative RT-PCR. Total RNA (15 μg) 
was used for cDNA synthesis by reverse transcription followed by the syn-
thesis of biotinylated cRNA through in vitro transcription. After cRNA 
fragmentation, we performed hybridization with a mouse A430 GeneChip 
(Aff  ymetrix, Inc.) (31). We performed quantitative RT-PCR using a 
LightCycler  (Roche), as described previously (52). The following primers 
were used: IL23A: 5′-C  T  G  C  T  T  G  C  A  A  A  G  G  A  T  C  C  A  C  C  -3′ (sense), 
5′-T  T  G  A  A  G  C  G  G  A  G  A  A  G  G  A  G  A  C  G  -3′ (antisense); IL12A: 5′-A  G  C  C-
T  C  C  T  C  C  T  T  G  T  G  G  C  T  A  -3′ (sense), 5′-T  G  T  G  C  T  G  G  T  T  T  T  A  T  C  T  T-
T  T  G  T  G  -3′ (antisense); IL12B: 5′-T  C  A  C  A  A  A  G  G  A  G  G  C  G  A  G  G  T  T  -3′ 
(sense), 5′-A  T  G  A  C  C  T  C  A  A  T  G  G  G  C  A  G  A  C  T  C  -3′ (antisense); and RANKL: 
5′-A  A  C  C  A  G  A  T  G  G  G  A  T  G  T  C  G  G  T  G  G  C  A  T  T  A  -3′ (sense), 5′-A  G  C  G  A  T-
G  G  T  G  G  A  T  G  G  C  T  C  A  T  G  G  T  T  A  G  -3′ (antisense). The level of mRNA ex-
pression was normalized with that of GAPDH expression in Fig. 5 A.
Statistical analyses. All data were expressed as the mean ± SEM (n = 4, 
unless otherwise indicated). Mann-Whitney U test was used for statistical 
  analyses (*, P < 0.05; **, P < 0.01), and comparisons were made between 
each sample and the control (not treated with T cells/cytokines or WT mice).
Online supplemental material. Fig. S1 shows the eff  ect of recombinant 
IL-4 on osteoclast precursor cells derived from WT or Stat6−/− mice in 
the RANKL–M-CSF system. Fig. S2 shows the list of genes whose expression 
was increased by IL-4 in osteoclast precursor cells (GeneChip analysis). 
Figs. S1 and S2 are available at http://www.jem.org/cgi/content/full/
jem.20061775/DC1.
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